Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02510261 · ClinicalTrials.gov registry record · Phase 3
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 3 study of Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT02510261: Completed Phase 3 study of Amyloidosis, sponsored by Alnylam Pharmaceuticals.
NCT02510261 is a Phase 3 study of Amyloidosis that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 211 participants, below the 1,121-participant average among 28 other Amyloidosis trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02510261, a Phase 3 study of Amyloidosis, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Primary Outcome
AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Patisiran
Study Locations (20)
Other
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Westmead
- Clinical Trial Site - Rio de Janeiro
- Clinical Trial Site - São Paulo
- Clinical Trial Site - Sofia
New York
- Clinical Trial Site - Cooperstown
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Missouri
- Clinical Trial Site - Joplin
- Clinical Trial Site - St Louis
California
- Clinical Trial Site - La Mesa
Colorado
- Clinical Trial Site - Aurora
Florida
- Clinical Trial Site - Jacksonville
Illinois
- Clinical Trial Site - Chicago
Maryland
- Clinical Trial Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2015-07-16 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 3 |
What the finished NCT02510261 record still lists
NCT02510261 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, below the 1,121-participant average among 28 other Amyloidosis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Patisiran is the first listed.
NCT02510261 names 20 study sites across 13 states, led by Other, New York, Missouri.
Frequently Asked Questions
What is clinical trial NCT02510261 about?
NCT02510261 is a clinical study titled "The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)". The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
What is the current status of trial NCT02510261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2015-07-16. Estimated completion is 2022-11-23.
What conditions does trial NCT02510261 study?
This clinical trial studies the following conditions: Amyloidosis.
What interventions are being tested in trial NCT02510261?
The interventions under investigation include: Patisiran (DRUG).
Who is sponsoring clinical trial NCT02510261?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02510261 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02510261's enrollment target sits among peer trials
211 10th of 28 higher than 19 of 28 other Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
COMPLETED · Phase 3
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI